Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Clinical pharmacogenetics in the treatment of schizophrenia].

Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology - 1 Jun 2005

Saito Manabu, Yasui-Furukori Norio, Kaneko Sunao

Abstract excerpt

Numerous investigations on metabolic enzymes, cytochrome P450 (CYP), have been conducted since 1990. In the psychiatric field, the focus has been on CYP2D6, which is a major enzyme involved in metabolism of antidepressants and antipsychotics. Poor metabolizers (deficit metabolizers) for CYP2D6 represent 7% among Caucasians, while they accouut for less than 1% of Asians. The frequency of a mutated allele for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Antipsychotic Agents
Share to Cytochrome P-450 CYP2D6

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Pharmacogenetics

Share to Polymorphism, Genetic

Share to Receptors, Dopamine D2

Share to Schizophrenia

Source

Identifiers

PMID: 16045195

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Clinical pharmacogenetics in the treatment of schizophrenia].PMID 16045195Read ↗

[Clinical pharmacogenetics in the treatment of schizophrenia].Semantic proximity Read ↗

[Pharmacogenetics and tailored drug treatment in schizophrenia].Semantic proximity Read ↗

The Role of Pharmacogenetic Testing in Optimizing Antipsychotic TherapySemantic proximity Read ↗

[Pharmaco-resistance and side effects of antipsychotics associated with poor metabolizer phenotype for cytochrome P450 2D6 in a context of early-onset schizophrenia: A case report].Semantic proximity Read ↗

[Pharmacogenetics in psychiatry: state of the art].Semantic proximity Read ↗

Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction.Semantic proximity Read ↗

Pharmacogenomics of antipsychotics efficacy for schizophreniaSemantic proximity Read ↗

[Clinical pharmacogenetics and future prospects in drug therapy].Semantic proximity Read ↗

Antipsychotic drug—aripiprazole against schizophrenia, its therapeutic and metabolic effects associated with gene polymorphismsSemantic proximity Read ↗

Deletion of the CYP2D6 gene as a likely explanation for the serious side effects of the antipsychotic drug pimozide: a case reportSemantic proximity Read ↗

[Pharmacogenetic-based risk assessment of antipsychotic-induced extrapyramidal symptoms].Semantic proximity Read ↗

Pharmacogenetics of schizophrenia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.